About Gilead Sciences
Gilead Sciences Inc. is a US-based biopharmaceutical company that has revolutionized the treatment of HIV, hepatitis, and viral diseases. Founded in 1987, Gilead is a world leader in antiviral therapies and is expanding into oncology and inflammation.
Virology Leadership
Gilead revolutionized HIV treatment with the development of single-tablet regimens like Atripla, Truvada, and Biktarvy. The company's HIV portfolio serves millions of patients worldwide, with Truvada also approved as PrEP for HIV prevention.
Hepatitis C Cure
Gilead transformed hepatitis C treatment with Sovaldi and Harvoni, achieving cure rates of over 95%. These breakthrough treatments have the potential to eliminate hepatitis C as a major public health threat.
Oncology Expansion
Through the acquisition of Kite Pharma, Gilead has become a leader in cell therapy with Yescarta and Tecartus for blood cancers. The company also has a growing pipeline in solid tumors and targeted therapies.
COVID-19 Response
Gilead developed Veklury (remdesivir), one of the first antiviral treatments approved for COVID-19, helping reduce hospitalization and recovery time for patients worldwide.
Leadership
Headquartered in Foster City, California, Gilead employs over 12,000 people. Daniel O'Day has served as Chairman and CEO since 2019, leading the company's expansion into oncology.